Our Mission & strategy
We intend to provide services and products across the globe, through innovation for a better quality of life for patients and by maximizing values for our stakeholders and customers.
BCI Pharma has a strategic plan that should enable it to have a competitive advantage in the biotech industry including:
•Leveraging business and R&D operations that focus on free cash flow generation
•Executing a viable financing strategy to fund operations and R&D projects
•Hiring and retaining seasoned management
•Researching and developing compelling science product candidates
•Securing intellectual property, technologies and business ideas for a compelling growth story vis-à-vis opportunity costs and competing investments.
Our product candidates will be evaluated and prioritized based on merit relative to other pipeline opportunities.
We will evaluate technical and market criteria for identifying projects with the highest strategic value, focussing on:
•Differentiation in product profile
•Unique mechanism of action
•Potential for establishing a new standard of care
•Improved side-effect profile or administration mode
•Therapeutic areas with unmet needs, clinical or commercial
•Returns that meet threshold NPV, internal rate of return, market size and peak sales potential
As part of its strategic planning, BCI Pharma will balance an opportunistic approach to leveraging assets that have high market potential with the right scientific decisions concerning projects that are technically viable. Such decisions on resource allocations and company objectives should set the course for how the staff develops tactical plans. The strongest assets should meet or exceed technical and commercial criteria. Platform technologies such as those with a mechanism of action that could work in more than one therapeutic category are other ways to boost productivity.
Naturally, BCI Pharma will need to achieve project milestones on time and on budget and to focus on the needs of investors or the investment climate. Examples of balanced strategic execution could involve a combination of:
•Partnering with companies that have complementary scale or functional areas of strength and capabilities
•Targeting therapeutic markets with demonstrated market returns and unmet needs
•Licensing or spinning out non-core assets that maintain the company’s focus
•Generating alliance revenues that further fund R&D of core assets